Fisher & Paykel Healthcare Corporation Limited (NZSX:FPH, ASX:FPH) announced today at its annual shareholders’ meeting that it has raised its earnings guidance for the financial year ending 31 March 2014.
Assuming an exchange rate of approximately 80 cents and taking into account increased underlying growth and margin improvement, the company expects net profit after tax to be in the range of NZ$90 million to NZ$95 million. The full year net profit guidance provided by the company in May, based on an exchange range of 80 cents to 85 cents for the NZ dollar to the US dollar, was NZ$85 million to NZ$90 million.
“Growth so far this year has continued to be robust and we expect first half revenue to grow approximately 15% in constant currency” commented Michael Daniell, Fisher & Paykel Healthcare’s CEO. “Demand for our RAC care products has continued to be particularly strong, with the proportion of our revenue from products used in new applications continuing to increase. We expect RAC constant currency revenue growth of about 18% for the first half.”
“For our OSA product group, mask revenue growth continues to be very encouraging and we are expecting first half constant currency revenue growth to also be well above market at about 14%.”
“There is a global trend to carefully manage growth in healthcare expenditure, which fits very well with our strategy of offering innovative medical devices that can help to reduce the overall healthcare costs per patient, by improving effectiveness and efficiency of care. That in turn is supportive of margins, as we increasingly demonstrate the benefits our products can offer” concluded Mr Daniell.
At current exchange rates, the company expects operating revenue for the first half to be approximately NZ$310 million and net profit after tax to be approximately NZ$43 million dollars. That would represent about 30% net profit growth, driven by a combination of robust revenue growth, improving gross margins and favourable hedging. Assuming an exchange rate of approximately 80 cents, the company now expects full year operating revenue to be in the range of NZ$625 million to NZ$645 million.
The company has provided the attached Chairman’s speech, CEO’s speech and slide presentation for the 2013 annual shareholders’ meeting as well as an update on the company’s foreign exchange hedging position as at today’s date.
Contact: Michael Daniell, MD/CEO on +64 9 574 0161 or Tony Barclay, CFO on +64 9 574 0119. For more information about the company visit our website www.fphcare.com.
Fisher & Paykel Healthcare Raises Earnings Guidance at 2013 Annual Shareholders' Meeting
Delivering respiratory support for spontaneously breathing patients
Full face masks designed for comfort and care
Providing Optimal Humidity for intubated patients
Establish effective spontaneous breathing or assist ventilation of the lungs
Respiratory support that replaces spontaneous breathing
Noninvasive respiratory support that provides a continuous distending pressure
Noninvasive respiratory support that delivers high flows of blended air and oxygen
Designed to work in harmony with the way patients naturally breathe while they sleep
F&P SleepStyle - designed to strike the balance between comfort and effective treatment
Nasal High Flow and Humidification for patients at home and in long term care
Home respiratory therapies that deliver humidification via a mask or tracheotomy tube to support and complement the airway’s natural-defense mechanisms
A flow range of 2 to 60 L/min allows for use across the care continuum - from the most acute hospital environment to the home
With Optiflow you can independently titrate flow and FiO2 according to your patient's needs
F&P Evora™ incorporates CapFit headgear that has been designed to be put on like a cap
The adaptable, reliable and robust humidification system. Use with Evaqua™ 2 circuit technology to minimize condensate
Updates and support for healthcare professionals
Looking after our people, suppliers, communities and the environment